Advertisement

Topics

BIO Investor Forum Session on Advancing Immuno–Oncology

20:11 EDT 18 Oct 2016 | BIO


At the 2016 BIO Investor Forum, the first session held was titled “The Intersection of Inflammation and Immuno-Oncology: Risks and Opportunities.” Moderated by Michael King, Managing Director and Senior Research Analyst at JMP Securities, panelist included: Jay Venkatesan, MD, President & Director, Alpine Immune Sciences Pablo Cagnoni, MD, President & Chief Executive Officer, Tizona Therapeutics Alex Szidon, PhD, Executive Director, Business Development & Licensing; Head of West Coast Innovation Hub, Merck & Co. Inc. Paul Read More >

Original Article: BIO Investor Forum Session on Advancing Immuno–Oncology

NEXT ARTICLE

More From BioPortfolio on "BIO Investor Forum Session on Advancing Immuno–Oncology"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...